(Q46704632)

24 December 2017

title

Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes (English)

1 reference

24 December 2017

0 references

1

1 reference

24 December 2017

Lise Tarnow

5

1 reference

24 December 2017

Coenraad Dirk Adriaan Stehouwer

6

object named as

C D A Stehouwer

1 reference

24 December 2017

Casper G. Schalkwijk

7

object named as

C Schalkwijk

1 reference

24 December 2017

author name string

P Rossing

2

1 reference

24 December 2017

K J Schjoedt

3

1 reference

24 December 2017

T Juhl

4

1 reference

24 December 2017

F Boomsma

8

1 reference

24 December 2017

E Frandsen

9

1 reference

24 December 2017

H-H Parving

10

1 reference

24 December 2017

language of work or name

English

0 references

publication date

12 March 2008

1 reference

24 December 2017

published in

Kidney International

1 reference

24 December 2017

volume

73

1 reference

24 December 2017

issue

12

1 reference

24 December 2017

page(s)

1419-1425

1 reference

24 December 2017

https://scigraph.springernature.com/pub.10.1038/ki.2008.68

exact match

0 references

cites work

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

Renin inhibition: what are the therapeutic opportunities?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

Effects of Converting-Enzyme Inhibition on Barrier Function in Diabetic Glomerulopathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

Enalapril improves albuminuria by preventing glomerular loss of heparan sulfate in diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

Prorenin Induces Intracellular Signaling in Cardiomyocytes Independently of Angiotensin II

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

Prorenin and the (pro)renin receptor--an update

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

Nonparallel effects of renin inhibitor treatment on plasma renin activity and angiotensins I and II in hypertensive subjects. An assay-related artifact

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

An easy radioimmunological microassay of renin activity, concentration and substrate in human and animal plasma and tissues based on angiotensin I trapping by antibody.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

A microassay for active and total renin concentration in human plasma based on antibody trapping

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.68

7 January 2021

Identifiers

DOI

10.1038/KI.2008.68

1 reference

24 December 2017

1 reference

24 December 2017